ERBB2 and gastrointestinal stromal tumor: At this time, assignment to one of four molecular classes does not appear to add value beyond the features already actionable for clinical decision-making in gastric tumors (e.g. carcinoma vs gastrointestinal stromal tumor, ERBB2 (HER2) gene amplification in metastatic carcinoma, stage).